ENDRA Life Sciences (NDRA)
(Delayed Data from NSDQ)
$0.20 USD
-0.01 (-6.77%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.21 +0.01 (6.60%) 6:56 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
ENDRA Life Sciences Inc. [NDRA]
Reports for Purchase
Showing records 1 - 20 ( 20 total )
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
Focused on Generating Robust TAEUS Data; Reiterate Buy With Adjusted PT of $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
TAEUS Progress Continues for De Novo FDA Submission; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
2Q22 Results Show a Building Base of TAEUS Installations; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
TAEUS Awareness Growing in the U.S.; Reiterate Buy Rating and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
TAEUS U.S. Pathway and Ex-U.S. Commercial Awareness Make Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
FDA Review of the TAEUS 510(k) Submission at a Snail''s Pace but Remains Active
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
TAEUS Momentum Positioned to Grow When COVID-19 Restrictions Ease in Europe; Reiterate Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
Staying Focused on European Initiatives While the FDA Review of TAEUS Continues; Reiterate Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
Staying Focused on European Initiatives While the FDA Review of TAEUS Continues; Reiterate Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
TAEUS Commercialization Is Within Sight; Reiterate Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
Final Program for Our Fourth Annual Virtual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
Program for Our Fourth Annual Virtual NASH Investor Conference, October 5
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
Completion of the TAEUS First-in-Human Feasibility Study During 3Q19 Marks a Major Milestone;
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
Healthcare - Accelerating the Pace: Perspectives From Our 3rd Annual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
Final Program for Our Third Annual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
Program for Our Third Annual NASH Investor Conference, October 21, New York
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
Progress Toward Advancing TAEUS Into Commercialization Sounds Closer; Reiterate Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: ENDRA Life Sciences Inc.
Industry: Medical - Instruments
TAEUS Aims to Fill the Gap in Imaging Capability; Initiating With a Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
|